Joseph B Quinn
Overview
Explore the profile of Joseph B Quinn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
93
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borroto-Esoda K, Waters J, Bae A, Harris J, Hinkle J, Quinn J, et al.
AIDS Res Hum Retroviruses
. 2007 Aug;
23(8):988-95.
PMID: 17725415
The presence of drug-associated mutations among ART-naive, HIV-1(+) patients may compromise the response to antiviral therapy. We evaluated the effect of preexisting drug-associated resistance mutations to the response in treatment-naive...
2.
Bartlett J, Chen S, Quinn J
HIV Clin Trials
. 2007 Aug;
8(4):221-6.
PMID: 17720662
Background: Many trials of antiretroviral therapy in treatment-naïve subjects have investigated the relative efficacy of the third drug in a treatment regimen. However, the nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) components...
3.
Benson C, van der Horst C, LaMarca A, Haas D, McDonald C, Steinhart C, et al.
AIDS
. 2004 Dec;
18(17):2269-76.
PMID: 15577539
Background: Once daily (QD) dosing facilitates regimen simplification and adherence to antiretroviral therapy. Emtricitabine (FTC) QD is a newly approved nucleoside reverse transcriptase inhibitor compared in this study to twice...
4.
Saag M, Cahn P, Raffi F, Wolff M, Pearce D, Molina J, et al.
JAMA
. 2004 Jul;
292(2):180-9.
PMID: 15249567
Context: Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective: To assess the efficacy and safety of emtricitabine as compared...
5.
Rousseau F, Wakeford C, Mommeja-Marin H, Sanne I, Moxham C, Harris J, et al.
J Infect Dis
. 2003 Nov;
188(11):1652-8.
PMID: 14639535
We conducted a randomized, open-label, 10-day study that compared the antiretroviral activity of emtricitabine (FTC) 25, 100, and 200 mg once daily and lamivudine (3TC) 150 mg 2 times/day in...